Stock GLTO GALECTO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Calendar Galecto, Inc.

Equities

GLTO

US36322Q1076

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.7048 USD +5.37% Intraday chart for Galecto, Inc. +3.42% -2.11%
Mar. 08 Galecto, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Galecto Shares Climb After Bone Marrow Disease Treatment Trial Yields Positive Results MT

Chart calendar Galecto, Inc.

3d9a9379.R0GUYNkgfIWpPQ0TCyUPOBaw-LgbLglhoL-vbrvJeDo.FSX4VbVtFPaaT1p8YWNETE6AtNJyVmwb6o7WXc--PwIwJ-Yjt1QW7vBMSA~d29ead499039766a5b3667782017b53a

Upcoming events on Galecto, Inc.

2024-07-30 Q2 2024 Earnings Release (Projected)

Past events on Galecto, Inc.

2024-04-25 Q1 2024 Earnings Release (Projected)
2023-09-27 04:45 pm Cantor Global Healthcare Conference
2023-09-11 07:00 am H.C. Wainwright Global Investment Conference
2023-07-31 04:05 pm Q2 2023 Earnings Release
2023-06-14 09:00 am Annual General Meeting
2023-06-08 04:00 pm Jefferies Global Healthcare Conference
2023-05-21 09:00 am ATS International Conference - Session: A67
2023-04-28 08:00 am Q1 2023 Earnings Release
2023-04-18 09:00 am American Association for Cancer Research Meeting - Abstract Number:LB173
2023-04-17 09:00 am American Association for Cancer Research Meeting - Abstract Number:LB104
2023-03-13 09:20 am Oppenheimer Healthcare Conference
2023-03-09 07:00 am Q4 2022 Earnings Release
2023-02-14 08:00 am SVB Securities Global Biopharma Conference
2022-12-10 06:30 pm American Society of Hematology Meeting
2022-11-16 02:25 am Jefferies London Healthcare Conference
2022-11-08 10:30 am American Association for the Study of Liver Diseases Meeting - Abstract Number:5014
2022-11-08 09:15 am Q3 2022 Earnings Release
2022-11-08 08:00 am Guliver-2 Phase 1b/2a Results Call
2022-11-07 01:00 pm American Association for the Study of Liver Diseases Meeting - Abstract Number:38895
2022-11-06 01:00 pm American Association for the Study of Liver Diseases Meeting - Abstract Number:3627

Annual results

Fiscal PeriodDecember 2019 2020 2021 2022 2023 2024
Net sales
Million USD		Released
Forecast
Spread 		0,00


0,00
0,00
- 		0,00
0,00
- 		0,00
0,00
- 		0,00
0,00
-
0,00

EBITDA
Million USD		Released
Forecast
Spread 		0,00


-33,4
-40,3
16.98%		-51,8
-54,3
4.66%		-60,7
-66,6
8.9%		0,00
0,00
-
0,00

EBIT
Million USD		Released
Forecast
Spread 		-39,0


-33,6
-38,4
12.41%		-52,2
-54,2
3.62%		-61,2
-66,7
8.21%		-39,9
-40,3
1.06%
-34,0

Earnings before Tax (EBT)
Million USD		Released
Forecast
Spread 		0,00


-34,8
-38,3
9.04%		-51,8
-53,3
2.9%		-61,6
-66,0
6.63%		-38,3
-38,5
0.47%
-33,7

Net income
Million USD		Released
Forecast
Spread 		0,00


-34,8
-40,6
14.27%		-51,8
-53,6
3.51%		-61,6
-64,5
4.53%		-38,3
-40,0
4.04%
-32,7

EPS
USD		Released
Forecast
Spread 		-421


-7,62
-5,10
-49.51%		-2,05
-2,13
3.76%		-2,43
-2,51
3.19%		-1,44
-1,51
4.64%
-1,20

Announcement Date02/09/2029/03/2117/02/2209/03/2308/03/24-

Quarterly results

Fiscal PeriodDecember 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales
Million USD		Released
Forecast
Spread 		0,00
0,00
-


0,00
0,00
- 		0,00
0,00
- 		0,00
0,00
- 		0,00
0,00
- 		0,00
0,00
- 		0,00
0,00
- 		0,00
0,00
-
0,00


0,00


0,00


0,00

EBITDA
Million USD		Released
Forecast
Spread











-13,4
-18,4
27.43%























EBIT
Million USD		Released
Forecast
Spread 		-13,5
-14,6
7.75%


-17,1
-13,8
-24.25%		-13,6
-16,9
19.35%		-13,5
-18,4
26.61%		-13,5
-17,7
23.77%		-11,2
-14,9
24.86%		-5,86
-13,3
56.08%		-6,67
-7,10
6.02%











Earnings before Tax (EBT)
Million USD		Released
Forecast
Spread 		-13,4
-14,3
6.23%











-13,0
-17,7
26.59%		-10,7
-14,9
27.65%		-8,14
-13,1
38.06%		-6,48
-6,66
2.72%











Net income
Million USD		Released
Forecast
Spread 		-13,4
-14,3
6.23%		-16,9


-16,9
-17,3
2.39%		-13,7
-17,3
20.64%		-14,1
-14,5
2.97%		-13,0
-16,1
19.04%		-10,7
-14,9
27.65%		-8,14
-12,7
36.06%		-6,48
-8,42
23.09%
-11,3


-10,5


-4,80


-4,30

EPS
USD		Released
Forecast
Spread 		-0,53
-0,56
5.36%		-0,67


-0,67
-0,69
2.9%		-0,54
-0,68
20.59%		-0,55
-0,57
3.51%		-0,51
-0,63
18.4%		-0,41
-0,59
30.11%		-0,30
-0,47
36.17%		-0,23
-0,31
25.81%
-0,29


-0,25


-0,14


-0,12

Announcement Date17/02/2229/04/2229/07/2208/11/2209/03/2328/04/2331/07/2306/11/2308/03/24----

Upcoming sector events for Galecto, Inc.

2024-04-28 HITGEN INC.: Q1 2024 Earnings Release (Projected)
2024-04-28 CASSAVA SCIENCES, INC.: Q1 2024 Earnings Release (Projected)
2024-04-29 DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD.: Q4 2023 Earnings Release
2024-04-29 ARVINAS, INC.: Q1 2024 Earnings Release (Projected)
2024-04-29 MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.: Q1 2024 Earnings Release
2024-04-29 WUXI APPTEC CO., LTD.: Q1 2024 Earnings Release
2024-04-30 04:05 pm EXELIXIS, INC.: Q1 2024 Earnings Release
2024-04-30 SUMMIT THERAPEUTICS INC.: Q1 2024 Earnings Release
2024-04-30 MACROGENICS, INC.: Q1 2024 Earnings Release (Projected)
2024-04-30 REGENXBIO INC.: Q1 2024 Earnings Release (Projected)
More events

Past sector events for Galecto, Inc.

2024-04-25 INVENTISBIO CO., LIMITED: Q4 2023 Earnings Release
2024-04-25 SHANGHAI MEDICILON INC.: Q1 2024 Earnings Release (Projected)
2024-04-25 SHANGHAI ALLIST PHARMACEUTICALS CO., LTD.: Q1 2024 Earnings Release (Projected)
2024-04-25 DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD.: Q1 2024 Earnings Release (Projected)
2024-04-25 SHANGHAI ALLIST PHARMACEUTICALS CO., LTD.: Q4 2023 Earnings Release
2024-04-25 REMEGEN CO., LTD.: Q1 2024 Earnings Release
2024-04-25 04:05 pm PTC THERAPEUTICS, INC.: Q1 2024 Earnings Release
2024-04-25 06:30 am SAGE THERAPEUTICS, INC.: Q1 2024 Earnings Release
2024-04-24 JIANGSU YAHONG MEDITECH CO., LTD.: Q1 2024 Earnings Release (Projected)
2024-04-24 BIO-THERA SOLUTIONS, LTD.: Q1 2024 Earnings Release (Projected)

Net sales - Quarter - Rate of surprise

Quarterly earnings - Rate of surprise

Net sales - Annual - Rate of surprise

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. GLTO Stock
  4. Calendar Galecto, Inc.